Abstract Library

#3369 Evaluating the significance of Chromogranin A and Synaptophysin in Pancreatic Neuroendocrine Tumors. A road towards finding independent biomarkers

Introduction: Chromogranin A (CgA) and Synaptophysin(SPY) are most commonly used immunohistochemical markers of Neuroendocrine cells and tumors. CgA is a marker for neuroendocrine secretory granules of gastrin and four pancreatic hormones and gastrin while SPY is a marker for synaptic vesicles in neuroendocrine cells.

Conference:

Presenting Author: Fatima A

Authors: Fatima A,

Keywords: chromogranin A, Synaptophysin, prognostic marker, pancreatic neuroendocrine, insulinoma,

#3305 177Lu-Dotatate efficacy and safety in functioning neuroendocrine tumors: A joint analysis of phase 2 prospective clinical trials

Introduction: Neuroendocrine tumors are a rare neoplasia. At least 25% of patients (pts) with advanced disease may have functioning neuroendocrine tumors (F-NETs) that can secrete bioactive peptides that can lead to specific symptoms like diarrhea that can be debilitating and life-threatening.Although symptom relief is available with somatostatin analogs (SSA), the disease eventually becomes refractory to SSA,leaving no proven treatment options

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Bongiovanni A

Authors: Bongiovanni A, Nicolini S, Ibrahim T, Foca F, Sansovini M,

Keywords: neuroendocrine tumor, carcinoid syndrome, neuroendocrine neoplasia, PRRT, insulinoma, 177Lu-Dotatate, functioning tumor,

#3241 Clinical features and management of paragangliomas in a tertiary university hospital

Introduction: Paragangliomas (PG) are rare neuroendocrine tumors that arise from the extra-adrenal paraganglia. The most frequent location is head and neck PG (HNPG), usually non-functioning tumors. PG present a high rate of genetic susceptibility mainly associated with SDHx mutation. Clinical presentation depends upon catecholamine secretion and tumor location. Surgery remains the standard treatment, although radiotherapy and systemic therapies can be considered for unresectable or metastatic disease.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Damaso S, Lopes Brás R, Paiva R, Macedo D, Fernandes I,

Keywords: paraganglioma, treatment, sdhb gene,

#2972 Characteristics and Management of Paragangliomas, 10 Years Experience

Introduction: Paraganglioma (PG) is a rare extra-adrenal neuroendocrine tumor, with common sites of presentation being abdomen, and head and neck region. The majority of PGs appear to be sporadic. However, almost half of cases are associated with an inherited syndrome. The highest malignancy rates are seen in paragangliomas (PGs) associated with SDHB mutations, which are usually abdominal and secretory.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Sardo E, Cameselle-Garcia S, Casteras A, Toledo R, Acosta D,

Keywords: Paraganglioma, SDHB mutations, Functioning Tumors,

#1772 Expression of Truncated Functional Subtype 5 Somatostatin Receptor Variant (sst5TMD4) in GEP-NETs and Association with Relevant Pathways Involved in NET Tumorigenesis

Introduction: Sst5TMD4, which is derived from a non-canonical splicing process of sst5 receptor, is overexpressed in several endocrine tumors and associated with a worse prognosis.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Diaz Perez A, Martínez-Fuentes A, García-Carbonero R, Luque R, Jimenez-Fonseca P,

Keywords: somatostatin receptor, neuroendocrine tumors,